• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The metabolism and disposition of 14C-fenofibrate in human volunteers.

作者信息

Weil A, Caldwell J, Strolin-Benedetti M

机构信息

Department of Pharmacology and Toxicology, St. Mary's Hospital Medical School, London, England.

出版信息

Drug Metab Dispos. 1990 Jan-Feb;18(1):115-20.

PMID:1970770
Abstract

The metabolic fate of a single dose of 14C-fenofibrate has been studied in a panel of eight healthy volunteers (four males and four females). In 7 days, a total of 84% of the administered dose was recovered, with 59% in the urine and 25% in the feces. The majority of the urinary 14C was excreted within 24 hr, whereas the bulk of the fecal 14C was recovered over the first 3 days after dosing. The major urinary metabolite was the ester glucuronide of fenofibric acid, accompanied by much smaller amounts of fenofibric acid and the benzhydrol and its glucuronide. The principal compound in feces was unchanged fenofibrate, together with smaller quantities of fenofibric acid and polar unknown metabolite(s). Experiments on the stability of fenofibryl glucuronide showed it to be less reactive than most ester glucuronides.

摘要

相似文献

1
The metabolism and disposition of 14C-fenofibrate in human volunteers.
Drug Metab Dispos. 1990 Jan-Feb;18(1):115-20.
2
The metabolism and disposition of fenofibrate in rat, guinea pig, and dog.
Drug Metab Dispos. 1988 Mar-Apr;16(2):302-9.
3
[Metabolism of fenofibrate and fenofibric acid in vivo and in cultures of liver epithelial cells (author's transl)].非诺贝特及非诺贝酸在体内及肝上皮细胞培养中的代谢(作者译)
Nouv Presse Med. 1980 Dec 22;9(49):3729-32.
4
Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man.实验动物和人类中氯贝酸及氯贝特代谢性结合的种属差异。
Drug Metab Dispos. 1983 Mar-Apr;11(2):97-102.
5
Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.新型抗焦虑候选药物CP-93,393在长 Evans 大鼠体内的代谢与排泄。通过液相色谱/串联质谱法区分区域异构体葡糖醛酸苷。
Drug Metab Dispos. 1997 Nov;25(11):1288-97.
6
Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.[14C]咪达非那新(一种用于治疗膀胱过度活动症的新化合物)在健康男性受试者口服给药后的吸收、代谢及排泄情况。
Drug Metab Dispos. 2007 Sep;35(9):1624-33. doi: 10.1124/dmd.107.016030. Epub 2007 Jun 13.
7
Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.非诺贝特与依折麦布之间药代动力学相互作用潜力的评估:一项在健康受试者中进行的I期、开放标签、多剂量、三周期交叉研究。
Clin Ther. 2006 Mar;28(3):373-87. doi: 10.1016/j.clinthera.2006.03.009.
8
Species differences in the chirality of the carbonyl reduction of [14C] fenofibrate in laboratory animals and humans.
Chirality. 1989;1(3):197-201. doi: 10.1002/chir.530010304.
9
The metabolic disposition of [14C]pivhydrazine, [14C]mebanazine, and [14C]benzylhydrazine in the rat.
Drug Metab Dispos. 1979 Nov-Dec;7(6):388-92.
10
Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.新型抗精神病药物齐拉西酮在人体内的代谢与排泄
Drug Metab Dispos. 1997 Jul;25(7):863-72.

引用本文的文献

1
Quantifying In Vivo Luminal Drug Solubilization -Supersaturation-Precipitation Profiles to Explain the Performance of Lipid Based Formulations.定量体内管腔药物增溶-过饱和-沉淀曲线解释基于脂质体制剂的性能。
Pharm Res. 2020 Feb 3;37(3):47. doi: 10.1007/s11095-020-2762-9.
2
Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential.具有抗胶质母细胞瘤潜力的非诺贝特化学修饰变体
Transl Oncol. 2019 Jul;12(7):895-907. doi: 10.1016/j.tranon.2019.04.006. Epub 2019 May 9.
3
Xenobiotic metabolomics: major impact on the metabolome.
外源性代谢组学:对代谢组的重大影响。
Annu Rev Pharmacol Toxicol. 2012;52:37-56. doi: 10.1146/annurev-pharmtox-010611-134748. Epub 2011 Aug 3.
4
New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS.基于超高效液相色谱-电喷雾电离-四极杆飞行时间质谱联用代谢组学结合液相色谱-串联质谱法研究非诺贝特在Sprague-Dawley大鼠体内的新代谢产物
Xenobiotica. 2009 Apr;39(4):345-54. doi: 10.1080/00498250802680827.
5
Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.使用基于超高效液相色谱-四极杆飞行时间质谱的代谢组学研究非诺贝特在食蟹猴体内的代谢情况。
Drug Metab Dispos. 2009 Jun;37(6):1157-63. doi: 10.1124/dmd.108.025817. Epub 2009 Feb 27.
6
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.过氧化物酶体增殖物激活受体激动剂作为人类T淋巴细胞中的抗炎介质:对动脉粥样硬化和移植相关动脉硬化的影响
Circ Res. 2002 Apr 5;90(6):703-10. doi: 10.1161/01.res.0000014225.20727.8f.
7
PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.过氧化物酶体增殖物激活受体α激活剂抑制细胞因子诱导的人内皮细胞中血管细胞黏附分子-1的表达。
Circulation. 1999 Jun 22;99(24):3125-31. doi: 10.1161/01.cir.99.24.3125.
8
Distribution of fenofibric acid in lipoprotein fractions of patients.非诺贝特酸在患者脂蛋白组分中的分布。
Eur J Drug Metab Pharmacokinet. 1998 Apr-Jun;23(2):287-94. doi: 10.1007/BF03189353.
9
Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.
Drugs. 1990 Aug;40(2):260-90. doi: 10.2165/00003495-199040020-00007.
10
Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphic?
Eur J Clin Pharmacol. 1991;41(2):153-9. doi: 10.1007/BF00265909.